VK2735
VENTURE
Viking Therapeutics · Phase 2 · Completed · Enrollment 176
The paper states the 2.5 mg and 15 mg ends of the weekly range, and the placebo result. It does not state each intermediate dose in the abstract cited here, so those registry arms stay n/r.
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- VK2735 2.5 mg: week 13 -9.1%
- VK2735 15 mg: week 13 -14.7%
- Placebo 13 weeks: week 13 -1.7%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.